Vistagen Therapeutics Inc. (NASDAQ:VTGN) saw an upside of 609.52% to $11.92 after adding $10.24 on Monday. The 5-day average trading volume is 3,643,023 shares of the company’s common stock. It has gained $24.7100 in the past week and touched a new high 2 times within the past 5 days. An average of 997,371 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 616,790.
VTGN’s 1-month performance is 554.95% or $10.4399 on its low of $1.6300 reached on 08/04/23. The company’s shares have touched a 52-week low of $1.62 and high of $10.30, with the stock’s rally to the 52-week high happening on 08/07/23. YTD, VTGN has achieved 285.76% or $9.1699 and has reached a new high 13 times. However, the current price is up 15.71% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
VTGN stock has a beta of 0.78. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 6.85.
Vistagen Therapeutics Inc.’s quick ratio for the period ended March 30 was 3.80, with the current ratio over the same period at 3.80. The firm’s gross profit as reported stood at $59.04 million against revenue of -$0.23 million.
Earnings Surprise
For the quarterly period ending March 30 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -36.47% to -$12.23 million, while revenue of -$9.76 million was 20.2% off the previous quarter. Analysts expected VTGN to announce -$1.5 per share in earnings in its latest quarter, but it posted -$1.75, representing a -16.70% surprise. EBITDA for the quarter stood at more than -$12.21 million. VTGN stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 9.01 million, with total debt at $2.72 million. Shareholders hold equity totaling $7.87 million.
Let’s look briefly at Vistagen Therapeutics Inc. (VTGN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 04 August was 97.71% to suggest the stock is trending Overbought, with historical volatility in this time period at 977.56%.
The stock’s 5-day moving average is $3.8340, reflecting a +573.62% or $10.4399 change from its current price. VTGN is currently trading +588.76% above its 20-day SMA, +180.48% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +206.80% and SMA200 by+273.55%.
Stochastic %K and %D was 26.48% and 26.33% and the average true range (ATR) pointed at 2.6685. The RSI (14) points at 95.54%, while the 14-day stochastic is at 46.06% with the period’s ATR at 1.7804. The stock’s 9-day MACD Oscillator is pointing at 2.3022 and 2.6869 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Vistagen Therapeutics Inc. (NASDAQ: VTGN), William Blair downgraded it to a Mkt perform rating. They previously had an Outperform rating on the stock. Analysts offering their rating for VTGN stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate VTGN as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.
What is VTGN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $7.50 and a high of $7.50, with their median price target at $7.50. Looking at these predictions, the average price target given by analysts is for Vistagen Therapeutics Inc. (VTGN) stock is $7.50.
